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Summary
Oncogene-inducedsenescence functions to limit tumordevelopment.However, acompleteunderstandingof thesignals that
trigger this type of senescence is currently lacking. We found that mutations affecting NF1, Raf, and Ras induce a global
negative feedback response that potently suppressesRas and/or its effectors.Moreover, these signals promote senescence
by inhibiting the Ras/PI3K pathway, which can impact the senescence machinery through HDM2 and FOXO. This negative
feedback program is regulated in part by RasGEFs, Sprouty proteins, RasGAPs, andMKPs.Moreover, these signals function
in vivo in benign human tumors. Thus, the ultimate response to the aberrant activation of the Ras pathway is a multifaceted
negative feedback signaling network that terminates the oncogenic signal and participates in the senescence response.Introduction
Aberrant activation of the Ras pathway plays an undisputed role
in human cancer (Downward, 2003). However, in some primary
cells activated Ras induces the accumulation of p53, p16, and
ARF and triggers cellular senescence (Serrano et al., 1997).
This apparent paradox can be reconciled by the observation
that Ras-induced senescence is bypassed by inactivating Rb
and p53, suggesting that this response may have evolved as
amechanism of tumor suppression (Serrano et al., 1997). Impor-
tantly, recent reports have further demonstrated that oncogene-
induced senescence occurs in vivo in response to Ras, Raf, and
PTEN mutations in human tumors and in mouse tumor models
(Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Micha-
loglou et al., 2005). In each case, a senescent population of cells
was detected in benign but not advanced lesions, supporting
the in vitro observation that activation of these pathways leads
to an initial burst of proliferation followed by cellular senes-
cence. Thus, these data suggest that senescence functions as
a mechanism of tumor suppression by limiting the development
of these benign lesions, in the absence of additional cooperating
mutations.
However, while these studies support an important biologi-
cal role for oncogene-induced senescence, the molecularCANCER CELL 10, 459–472, DECEMBER 2006 ª2006 ELSEVIER INC. DOmechanisms that trigger this response are not completely un-
derstood. Certainly some of the signals that contribute to the
senescence response have been identified. For example, acti-
vation of the Ras/Raf pathway is known to mediate some of its
effects through activation of p16 and ARF (Ohtani et al., 2001;
Wei et al., 2001; Zhu et al., 1998). However, many additional
questions remain unanswered. First, it appears that some cells
are sensitive to oncogene-induced senescence, while other
cell types are not (Collado et al., 2005; Tuveson et al., 2004), al-
though there is no current mechanistic explanation for this ob-
servation. In addition, the historical definition of a senescent
cell is one that cannot activate immediate-early genes in re-
sponse to growth factors (Seshadri and Campisi, 1990). This ob-
servation implies that there must be a signal(s) that actively sup-
presses early signal transduction events in senescent cells,
which presumably contributes to their inability to proliferate.
However this aspect of senescence cannot be intuitively ex-
plained by the known functions of p53 and Rb.
To address these questions, we first developed a system in
which we could study cell types that might respond differently
to the same oncogenic insult. Specifically, we examined the
consequences of inactivating the NF1 tumor suppressor. The
NF1-encoded protein, neurofibromin (NF1), is a Ras GTPase-
activating protein (GAP) and has been shown to function asS I G N I F I C A N C E
While activation of the Ras pathway generally promotes tumorigenesis, in some benign tumors deregulated oncogenic signaling trig-
gers cellular senescence. Consequently, ‘‘oncogene-induced senescence’’ (OIS) is thought to limit the progression of these lesions.
However, the molecular mechanisms underlying OIS are not completely understood, and it is unclear why some cells senesce in re-
sponse to oncogenic insult while others do not. We have found that ‘‘sensitive cells’’ trigger a negative feedback signaling network,
designed to terminate aberrant signals. Moreover, this response actively promotes senescence and ismediated by numerous proteins
known to regulate Ras signaling. Finally, this negative feedbackprogram functions in benign human tumors. Thus, these studies provide
mechanistic insight into OIS and reveal additional genes that function in tumor suppression.I 10.1016/j.ccr.2006.10.003 459
A R T I C L Esuch in vitro and in vivo (reviewed in Cichowski and Jacks,
2001). Loss-of-function mutations in NF1 underlie the familial
cancer syndrome neurofibromatosis type I, which is character-
ized by the development of a variety of tumorigenic and nontu-
morigenic symptoms. Notably, many of the lesions associated
with NF1 are benign. We and others have previously shown
that Ras is hyperactivated in NF1-deficient mouse cells and
human tumor cell lines (Basu et al., 1992; Bollag et al., 1996;
Cichowski et al., 2003; DeClue et al., 1992; Johannessen
et al., 2005; Kim et al., 1995). Accordingly, we reasoned that
acutely inactivating neurofibromin, via an RNAi strategy, would
provide a unique means of activating physiological levels of
Ras in different cell lines, which cannot be accomplished by
ectopically expressing an activated Ras protein.
Interestingly, loss of neurofibromin in primary mouse embry-
onic fibroblasts (MEFs) resulted in their immortalization, similar
to the phenotype of MEFs expressing a single mutant K-ras al-
lele (Tuveson et al., 2004). In contrast, acute neurofibromin de-
ficiency in primary human cells rapidly triggered senescence.
Surprisingly, while Ras, AKT, and ERK activity was sustained
in MEFs upon neurofibromin loss, in primary human cells these
proteins were transiently activated and then quickly suppressed
to lower than baseline levels. This negative feedback response
was not limited to NF1 knockdown (NF1KD) cells, as a mutant
Raf allele also induced a rapid and dramatic suppression of
Ras and the PI3K/AKT pathway. In both cases, this negative
feedback response appeared to bemediated by several classes
of proteins known to suppress Ras signaling. In addition, we
found that the suppression of PI3K in this context can interface
with Rb and p53 pathways minimally through its effects on
HDM2 and FOXO and does so in vivo in benign human tumors.
Taken together, these data suggest that one mechanism by
which a cell protects itself from oncogenic insult is by initiating
a fail-safe negative feedback signaling program that ultimately
promotes the senescence response. Thus, these negative regu-
latory proteins may be unappreciated components functioning
to limit the development of benign tumors.
Results
Effects of NF1 loss on primary human and mouse cells
To investigate mechanisms that contribute to oncogene-in-
duced senescence, the effects of neurofibromin deficiency
were compared in several cell systems in which Ras-mediated
senescence has been well studied (Serrano et al., 1997; Wei
andSedivy, 1999). Human IMR90 or BJ fibroblastswere infected
with lentiviruses encoding shRNAs recognizing two different
sequences within the NF1 gene. Both constructs suppressed
neurofibromin expression and induced senescence within
5 days (Figure 1A). Both IMR90 and BJ fibroblasts became sen-
escent with roughly the same kinetics, as determined by an ob-
served growth arrest, senescence-associated b-galactosidase
activity (SA-b-Gal), and a flattened cellular morphology (Fig-
ure 1A and data not shown). Notably, p120RasGAP shRNAs
also triggered cellular senescence, supporting the conclusion
that senescence in these cells was triggered by endogenous
Ras activation and was not due to an uncharacterized function
of neurofibromin (Figure 1B).
Because physiological levels of oncogenic Ras have been
reported to immortalize murine fibroblasts, rather than induce460senescence (Guerra et al., 2003; Tuveson et al., 2004), we also
assessed the biological effects of neurofibromin deficiency in
primary MEFs. Consistent with the phenotype conferred by an
activated K-ras allele, Nf1-deficient MEFs did not undergo pre-
mature senescence but were immortal. This phenotype was ob-
served in cells where neurofibromin expression was abolished
through the use of the same shRNA-encoding construct used
in primary human cells, and in several independently derived
Nf1-deficientMEF lines (Figure 1C and Figure S1A in the Supple-
mental Data available with this article online). Immortalized Nf1-
deficient and NF1KDMEFsmaintained an intact p53 response to
doxorubicin and retained ARF expression (Figure S1B), indicat-
ing that these cells did not spontaneously immortalize by acquir-
ing defects in these pathways. These results demonstrate that
the same genetic event can trigger dramatically different biolog-
ical responses in primary mouse cells (MEFs) versus primary
human fibroblasts. While species-specific differences may con-
tribute to these observed effects, based on additional findings
described below, we believe that this observation reflects differ-
ent biochemical responses to this aberrant signal in these partic-
ular cell types.
p53 and Rb pathways mediate senescence triggered
by the loss of NF1
Senescence in response to Ras activation in human cells is me-
diated by the activation of the Rb and p53 pathways (Serrano
et al., 1997); therefore, the expression of these proteins was ex-
amined in NF1KD cells. Similar to what has been reported in cells
ectopically expressing an activated Ras allele, loss of neurofi-
bromin induced the accumulation of p53 and the activation of
Rb, as demonstrated by reduced levels of hyperphosphorylated
Rb (Figure 2A). To assess the relative contribution of these path-
ways to the senescence response, Rb and p53 pathways were
inactivated in isolation or together. The p53 pathway was dis-
rupted by expressing a dominant-negative p53, and the Rb
pathway was inactivated by expressing an SV40 Large T mu-
tant, capable of binding and inactivating all three Rb family
members, but deficient in its ability to bind p53 (Hahn et al.,
2002). Inactivation of either the Rb or p53 pathway resulted in
a partial decrease in the percentage of senescent cells but, in
isolation, was unable to completely override the effects of NF1
inactivation (Figure 2B). However, senescence was dramatically
inhibited in cells expressing the wild-type SV40 Large T antigen,
which binds and inactivates Rb family members and p53. These
results indicate that both the Rb and p53 pathways mediate
NF1-related senescence in human cells.
Ras and Ras effector pathways are rapidly inactivated
in human cells following oncogenic insult
To examine the effects of neurofibromin loss on cell signaling,
the activation of ERK and AKT were assessed in human cells
following exposure to NF1-specific, shRNA-expressing lentivi-
ruses. Neurofibromin expression was significantly decreased
within 2 days after infection (Figure 3A). Concomitant with this
decrease was an increase in ERK and AKT activity as assessed
by their phosphorylation status. Surprisingly, however, the acti-
vation of these proteins peaked at day 2 and began to decrease
rapidly thereafter. Phospho-AKT and phospho-ERK levels were
potently suppressed by days 3 and 4, respectively. Ras-GTP
levels exhibited similar kinetics: Ras-GTP levels were elevated
2 days after infection andwere suppressed to levels significantlyCANCER CELL DECEMBER 2006
A R T I C L EFigure 1. Loss of neurofibromin induces senescence in human fibroblasts but immortalizes mouse embryonic fibroblasts
A:Growth curve and immunoblot of normal human IMR90 fibroblasts infected with a control lentiviral vector (V), or lentiviruses expressing NF1 shRNAs. At each
cell passage, cells were replated and SA-b-Gal activity and morphology were assessed (bottom panels). The error bars indicate the range of three replicates.
B: SA-b-Gal activity in response to p120RasGAP knockdown.
C: Proliferative properties of wild-type and NF1KD MEFs. Doxorubicin (DR) treatment (0.2 mg/ml for 18 hr) was used at passage 21, to assess p53 status.lower than cycling vector-infected cells several days later (Fig-
ure 3B). Phospho-AKT levels were similarly reduced to levels
below baseline (Figure S2). Importantly, at both time points cellsCANCER CELL DECEMBER 2006were plated at an equal density, eliminating any potentially con-
founding effects of cell density in these studies. Thus, while the
loss of neurofibromin initially triggers the activation of Ras and461
A R T I C L Eits effectors in primary human cells, these pathways are potently
suppressed shortly thereafter.
These observations were in stark contrast to the effects of
neurofibromin loss in MEFs, which did not senesce but rather
became immortalized (Figure 1C and Figure S1). Notably, we
and others have extensively demonstrated that NF1 deficiency
in MEFs results in a sustained activation of Ras and Ras effector
pathways (Cichowski et al., 2003; Hiatt et al., 2001; Johannes-
sen et al., 2005; Figure 3C). Moreover, we found that Rb and
p53 were not activated in response to the acute loss of NF1
(Figure 3C). We do not believe that these observations are due
to inherent species-specific differences between mouse and
human cells, as mouse cells do undergo senescence in re-
sponse to oncogenic insult in vivo (Chen et al., 2005; Collado
et al., 2005). Moreover, Nf1 deficiency results in a growth arrest
of murine Schwann cells in culture (Kim et al., 1995). Therefore,
Figure 2. Senescence triggered by neurofibromin deficiency requires Rb
and p53 pathways
A: Immunoblots demonstrating that p53 and Rb are activated in response to
NF1 loss.
B: NF1 was inactivated in cells previously infected with an empty vector
(pMKO.1), LgT, a dominant-negative p53 (p53DD), or a Large T D234-444
mutant. SA-b-Gal expression is shown.462we favor the possibility that the differential biochemical and bio-
logical responses to aberrant Ras activation represent differ-
ences in the signaling network components that are present in
these particular cell types. These results also support the possi-
bility that traditional signals that are triggered by this genetic
event may not be sufficient to induce senescence alone, and
that additional cooperating signals may be required to amplify
this response in MEFs.
Suppression of the Ras pathway is sufficient to trigger
cellular senescence
Notably, in IMR90 and BJ cells, Ras signaling was suppressed
prior to the initiation of senescence. To examine whether this
suppression might actively contribute to the senescence re-
sponse, IMR90 andBJ fibroblastswere infectedwith a retrovirus
that expresses the catalytic GAP-related domain (GRD) of neu-
rofibromin. Expression of this domain has previously been
shown to decrease Ras-GTP levels (Hiatt et al., 2001; Johannes-
sen et al., 2005). Consistent with these findings, GRD expres-
sion resulted in a significant decrease in the activation of AKT
and ERK (Figure 3D) and induced senescence in both IMR90
and BJ cells (Figure 3E), suggesting that suppression of Ras is
sufficient to trigger cellular senescence.
Importantly, GRD expression resulted in the activation of both
the Rb and p53 pathways (Figure 3D), and the same cell cycle
inhibitors were upregulated in human cells treated with NF1-
specific shRNA constructs (Figure 3F), with the exception of
p16, which was only activated in NF1KD- and not GRD-express-
ing cells. This latter finding was predicted, as activation of ERK
increases p16 expression via its effects on ETS transcription
factors (Ohtani et al., 2001), which would only be expected to
happen in response to neurofibromin loss. In addition, p16 ex-
pression becomes Raf independent in cells expressing an in-
ducible Raf allele, once p16 is upregulated (Zhu et al., 1998).
Nevertheless, the observations that (1) the Ras signal is termi-
nated prior to senescence in NF1-deficient cells, that (2) Ras
suppression is sufficient to trigger senescence, and that (3)
Ras inactivation results in the activation of both the Rb and
p53 pathways suggest that this event actively participates in
the senescence response and may do so by cooperating with
or amplifying previously described signals. In this context it is
notable that the suppression of the PI3K/AKT pathway, in partic-
ular, is coincident with the induction of p16 in response to acute
NF1 deficiency (Figure S3). Therefore this signal is poised to
function along with p16 in mediating this process. The signifi-
cance of PI3K/AKT suppression will be addressed in Figure 5.
The aberrant activation of Raf and Ras triggers a global
negative feedback signaling program
To determine whether the suppression of Ras and/or Ras effec-
tor pathways is a common mechanism leading to senescence,
we looked for evidence of a negative feedback signal in re-
sponse to Raf activation, which also triggers the senescence
of primary human cells (Zhu et al., 1998; Figure 4A). When an in-
ducible, activated Raf allele was expressed in BJ cells, Ras-GTP
levels were significantly reduced within 30min (Figure 4A). Strik-
ingly, Ras-GTP levels were nearly abolished 24 hr later, suggest-
ing the possible involvement of both short- and longer-term
mechanisms of suppression.
To dissect themolecular events underlying this negative feed-
back pathway, we first examined the effects of Raf activation onCANCER CELL DECEMBER 2006
A R T I C L EFigure 3. Negative feedback suppression of the
Ras pathway underlies cellular senescence
A: Immunoblots of IMR90 lysates showing the dy-
namic effects of NF1 loss on pERK and pAKT
levels. Intervening lanes are spliced out where in-
dicated, but all time courses represent data from
the same immunoblot.
B: Ras activation in NF1KD versus control cells on
days 2 and 6 (see Experimental Procedures).
The long exposure is shown to highlight the de-
crease in Ras-GTP levels between vector and
NF1 knockdown cells at this latter time point.
C: pAKT, Rb, and p53 immunoblots of MEF lysates
in response to NF1 deficiency.
D: Immunoblots of lysates from BJ fibroblasts in-
fected with retrovirus expressing the GRD of neu-
rofibromin, 9 days postinfection.
E: SA-b-Gal staining of fibroblasts (IMR90 and BJ)
infected with the GRD of neurofibromin.
F: Immunoblots of cell lysates from BJ fibroblasts
in response to NF1 loss, 6 days postselection.known Ras regulators: RasGEFs and RasGAPs. Notably, the
exchange factor SOS can be phosphorylated by ERK, which
has been shown to result in its inactivation (Corbalan-Garcia
et al., 1996; Dong et al., 1996). We found that SOS became
phosphorylated in this system within 30 min of Raf activation,
as demonstrated by a shift in its electrophoretic mobility, and
confirmed by calf intestinal phosphatase (CIP) treatment, which
eliminated the slower migrating species (Figure 4B). In addition,
Raf significantly increased the protein levels of p120RasGAP
within 24–72 hr (Figure 4B). These observations suggested
that multiple signals, involving posttranslational and perhaps
transcriptional events, might be involved in triggering this nega-
tive feedback loop.
To obtain a more comprehensive view of the signals partici-
pating in this response, a preliminary microarray screen was
performed on Raf-expressing cells as a means of identifying po-
tential candidate genes. From this list of differentially regulated
genes, those known to regulate Ras signaling were selected
for real-time PCR and Western analysis (Figures 4C and 4D).
Strikingly, several classes of genes, encoding proteins knownCANCER CELL DECEMBER 2006to suppress Ras signaling at many levels, were shown to be
exquisitely sensitive to sustained Raf activation. Among these
candidates, Sprouty genes (2 and 4) were the most highly upre-
gulated in response to Raf activation. Sprouty was originally
identified in a Drosophila screen as a suppressor of FGF recep-
tor signaling and has subsequently been shown to suppress the
Ras pathway, potentially acting at many levels (reviewed in Kim
and Bar-Sagi, 2004). In addition, four RasGAP-encoding genes,
including p120RasGAP, were transcriptionally upregulated in
response to Raf activation, which would also be expected to
directly suppress Ras-GTP levels. RasGRP1, which encodes a
Ras exchange factor, was also downregulated by more than
6-fold in response to Raf activation. Thus, Raf activation ap-
pears to suppress Ras-GTP levels directly through a variety of
redundant mechanisms, although because of this redundancy
we were not able to experimentally determine which of these
events are absolutely critical in this system. Interestingly, other
suppressors of Ras signaling known to act on downstream com-
ponents were also identified. The Sprouty-related genes Spred-
2 and -4 were also highly upregulated and have been shown to463
A R T I C L EFigure 4. Aberrant Raf activation suppresses Ras via multiple distinct mechanisms
A: SA-b-Gal staining of IMR90 infected with Raf1-CAAX (left panel). BJ fibroblasts, expressing an inducible Raf construct, were treated for 30 or 90 min with
tamoxifen (4-HT, 1 mM). Ras-GTP levels were assessed using a Ras pulldown (PD) assay. Control immunoblots on total cell lysates (TCL) are shown (middle
panel). Ras-GTP levels after 24 hr of 4-HT (right panel).
B: SOS immunoblots of BJ cells expressing the inducible Raf construct in the presence and absence of CIP (added to lysates) (top). p120RasGAP protein levels
increase as pAKT levels decrease (bottom).
C: BJ cells expressing the inducible Raf were treated for 42 hr with tamoxifen (1 mM) or ethanol. Real-time PCR was performed in triplicate on the listed genes,
and fold changes were calculated.
D: Immunoblot analysis of lysates from C.
E: Real-time PCR analysis of genes in response to NF1 loss, as compared to cycling, vector-expressing cells.
F: SA-b-Gal staining and immunoblots of BJ cells expressing exogenous Sprouty 2.suppress Raf signaling, by affecting the Ras/Raf interaction
(reviewed in Kim and Bar-Sagi, 2004). Finally, several dual spec-
ificity kinases (DUSPs), also referred to as MAP kinase phos-
phatases, known to inactivate ERK, were transcriptionally464upregulated in response to Raf, consistent with a previous study
that identified genes that are upregulated in response to Ras
mutations in mouse and human tumors (Sweet-Cordero et al.,
2005). Importantly, the loss of neurofibromin also triggered theCANCER CELL DECEMBER 2006
A R T I C L EFigure 5. Inactivation of the PI3K pathway trig-
gers senescence
A: BJ fibroblasts, expressing an inducible form
of Raf, were treated with 1 mM tamoxifen (+) or
ethanol (2). Immunoblots demonstrate the
dramatic decrease in pAKT levels.
B: Percentage of SA-b-Gal-positive IMR90 cells
after mock, DMSO, LY294002, and PD98059 treat-
ments lasting 2 or 4 days. The error bars indicate
the range of three replicates.
C: SA-b-Gal staining of BJ cells treated with
DMSO, LY294002, and wortmannin, or cells ex-
pressing an HA-PTEN construct (left). Control
immunoblots are shown (right).upregulation of Sprouty genes and DUSP genes, as well as a
modest activation of RasGAP-encoding genes (Figure 4E). The
upregulation of these genes was overall more subtle in response
to NF1 loss, and interestingly, while the same classes of genes
were affected, the specific genes identifiedwere different. These
differences may reflect differences in signal intensity and/or the
coordinate effects of activating both theRaf andPI3 kinasepath-
way in NF1-deficient cells.
These data indicate that one of the earliest responses to the
aberrant activation of the Ras pathway is the initiation of a neg-
ative feedback signaling network, designed to terminate the re-
sulting oncogenic signal. Given that our analysis was primarily
designed to detect differences in gene and protein expression,
it is likely that these findings are an underrepresentation of the
signals that may function in this context, and that more may oc-
cur via posttranslational mechanisms. Moreover, because of
this redundancy, loss of any one of these signals alone would
not be expected to prevent senescence in this system, espe-
cially given that the inactivation of p53 or Rb alone is unable
to bypass this response. However, we found that senescence
could be triggered by recapitulating some of these signals.
For example, ectopic expression of Sprouty 2 was sufficient
to trigger a senescence response (Figure 4F). In addition, an in-
crease in total cellular GAP activity, via the ectopic expression
of a catalytic GAP domain, induced senescence as shown in
Figure 3E. Taken together, these data further support theCANCER CELL DECEMBER 2006involvement of these signals in promoting oncogene-induced
senescence.
In the analysis described above, several genes were identified
that encode proteins known to affect Ras-GTP levels directly.
However, some of these signals would not be expected to im-
pact mutant Ras alleles. To determine if ERK and AKT were sim-
ilarly suppressed in response to a mutant Ras allele at later time
points, the kinetics of ERK and AKT activation in human cells
infected with a RasV12-expressing retrovirus was examined.
Shortly after Ras was introduced, AKT and ERK were potently
activated; however, ERK and AKT were dramatically inhibited
shortly thereafter (Figure S4). While we did not attempt to iden-
tify the specific mediators of this response, these results further
support the notion that the ultimate response of primary human
cells confronted with the aberrant activation of the Ras pathway
induced by different genetic events is to dramatically attenuate
Ras signaling, which can occur at many levels.
Suppression of the PI3K pathway mediates
the senescence response
Because the suppression of Ras triggered cellular senescence,
suppression of known effector pathways might be expected to
mediate this effect. Interestingly, in response to an inducible
Raf allele, the PI3K/AKT pathway was completely suppressed
within 48–72 hr in BJ cells, while ERK activity was reduced but
was never completely inactivated (Figure 5A). This observation,465
A R T I C L EFigure 6. Oncogenic insult regulates HDM2 and
FOXO proteins
A: BJ fibroblasts were treated for the indicated
times with LY294002. Rb, p53, and p-AKT levels
were assessed by immunoblot.
B: Levels of p-HDM2 were assessed by immuno-
blotting lysates from BJ cells treated with DMSO
(D) or LY294002 (LY) for 24 hr, from cells expressing
an inducible Raf construct 48 hr after induction,
or in NF1KD cells after 6 days.
C: Luciferase activity of a FOXO reporter in the
presence of exogenous FOXO1 or FOXO3, 72 hr
after Raf induction in BJ cells. The error bars indi-
cate the range of three replicates.
D: A phosphorylation mutant of FOXO1 (FKHR-
AAA) induces senescence and Rb activation in
human fibroblasts.along with the delayed suppression of ERK relative to AKT in
NF1KD cells, suggested that suppression of the PI3K pathway
might play a greater role in mediating senescence. To investi-
gate the relative contributions of these pathways, wild-type
IMR90 cells were treated with the PI3K inhibitor LY294002 or
the MEK inhibitor PD98059. In less than 3 days, 60% of the cells
treated with the PI3K inhibitor became senescent (Figures 5B
and 5C and data not shown), as has been previously reported
(Tresini et al., 1998). The PI3K inhibitor wortmannin and the
ectopic expression of PTEN, which inactivates PI3K signaling,
induced the same response (Figure 5C). In contrast, the MEK in-
hibitor only slightly increased the number of SA-b-Gal-express-
ing cells. Therefore, we conclude that suppression of the PI3K
pathway is likely to be the primary mechanism by which this
negative feedback loop promotes senescence.
Importantly, PI3K inhibition resulted in the activation of Rb
and p53, demonstrating that the suppression of this pathway
can impact these known senescence regulators (Figure 6A).
To define the mechanism by which this occurred, we first exam-
ined pathways that are known to be affected by PI3K/AKT sig-
naling. Notably, MDM2 phosphorylation by AKT at serine 166
(and 186) has been reported to activate its ubiquitin ligase activ-
ity toward p53 (Ogawara et al., 2002). Accordingly, HDM2 phos-
phorylated at serine 166 was readily detected in cycling BJ cells
(Figure 6B). However, HDM2 phosphorylation levels were466significantly reduced in cells treated with a PI3K inhibitor and
were reduced to an even greater extent in cells exposed to an
activated Raf allele for 48 hr, or in NF1KD cells. Thus, this repre-
sents one mechanism by which suppression of AKT may trans-
duce its effects on p53 in these cells.
Because one of the most well-characterized events that oc-
curs in response to suppression of the PI3K pathway is the ac-
tivation of FOXO proteins, we also examined this pathway in this
system. Active FOXO proteins are known to induce a growth ar-
rest and have been hypothesized to be tumor suppressors
(reviewed in Greer and Brunet, 2005).Strikingly, Raf activation
triggered the activation of FOXO proteins with the same rapid
kinetics (48 hr) observed for the suppression of PI3K/AKT (Fig-
ure 6C). Moreover, the expression of a constitutively activated
FOXO1 mutant, incapable of being inactivated by AKT, rapidly
triggered cellular senescence along with the activation of Rb,
but not p53 (Figure 6D). While we did not extensively character-
ize the expression of FOXO targets in these cells, we did confirm
that BTG1, a FOXO target implicated in growth arrest, was tran-
scriptionally upregulated in Raf-expressing cells within 48 hr by
4.25-fold (60.06) (Figure S5). Thus, taken together these results
suggest that the dramatic suppression of the PI3K/AKT path-
way, in the context of Raf and NF1mutations, may promote se-
nescence, in part, through the inhibition of HDM2 activity and
activation of FOXO proteins. These proteins may or may notCANCER CELL DECEMBER 2006
A R T I C L EFigure 7. Senescence occurs in human neurofi-
bromas in vivo
A and B: SA-b-Gal expression in dermal neurofi-
bromas. C: A bright-field picture of a SA-b-Gal-
stained section (blue) overlaid with a dark-field
image of immunofluorescent neurofibromin
staining (pink). Dermal neurofibroma sections,
first stained for SA-b-Gal, were then stained for
p16 (D), AP2-a (E), and Krox-20 (F). G: p-ERK.
H: p-AKT (top large image and middle small im-
ages) and FOXO1 (bottom small images). High-
magnification images of single cells demon-
strate the nuclear localization of FOXO1 and
an absence of nuclear p-ERK or p-AKT staining
in all senescent cells. For FOXO1 analysis, sections
were counterstained with hematoxylin to dem-
onstrate surrounding negative cells.be the only mediators of this process, and the specific signals
may differ between cell types. Nevertheless, these results indi-
cate that the suppression of PI3K can impact the senescence
response on many levels and therefore is an unappreciated
and multifaceted signal that is engaged in response to the
aberrant activation of Ras and Raf.
Senescence in benign human tumors from NF1 patients
To assess the in vivo relevance of this negative feedback pro-
gram, we examined tumors from patients with neurofibromato-
sis type 1. Specifically, benign peripheral nervous system tu-
mors, known as neurofibromas, were examined. While these
tumors are benign, a subset of lesions, plexiform neurofibromas,
can progress to malignancy (Riccardi, 1992). However, for this
study we focused on dermal neurofibromas, which are typically
very small and never becomemalignant. One of the unusual fea-
tures of neurofibromas is their cellular heterogeneity: consistingCANCER CELL DECEMBER 2006of Schwann cells, fibroblasts, perineurial cells, neurons, and
mast cells (reviewed in Cichowski and Jacks, 2001). Human ge-
netic studies and mouse modeling efforts indicate that neurofi-
broma development is triggered by a somatic second-hit muta-
tion in the NF1 gene that occurs in a Schwann cell progenitor
(Zhu et al., 2002). However, while these NF12/2 cells serve as
a seed population to initiate tumorigenesis, surrounding cells
are recruited in the process of tumor development. As a conse-
quence, a high percentage of cells distributed throughout neu-
rofibromas are merely heterozygous for an NF1 mutation.
Notably, SA-b-Gal-expressing cells were observed in five out
of five dermal neurofibromas isolated fromNF1 patients (Figures
7A and 7B). Given the cellular complexity of these lesions, which
are comprised of numerous NF1+/2 cells as described above,
the dispersed pattern of SA-b-Gal-expressing cells was ex-
pected. In addition, tumors are often resected when they are
symptomatic and growing, and therefore would not be467
A R T I C L Epredicted to be completely ‘‘senescent.’’ Regardless, while the
percentage of SA-b-Gal cells was small (ranging from 2.7%–
5.1% in five tumors), SA-b-Gal activity was never found in cells
that retained neurofibromin expression (NF1+/2 cells), further
indicating that senescence is triggered by NF1 deficiency
(Figure 7C).
To determine whether these SA-b-Gal-expressing cells ex-
hibited additional markers of senescence, immunohistochemis-
try was performed using antibodies to p16 (Figure 7D). Notably,
100% percent of the SA-b-Gal-expressing cells expressed p16,
as assessed by examining over 300 cells from five individual tu-
mors. However, in all cases there was a higher percentage of
p16-expressing cells than SA-b-Gal-expressing cells (8.1% ver-
sus 5.1% in this tumor), similar to observations in benign mela-
nocytic nevi, further supporting the hypothesis that p16 expres-
sion on its own may not be sufficient to induce senescence in
these cells, and additional signals could be required (Michalo-
glou et al., 2005).
Senescence occurs in a progenitor cell population
If senescence limits the development of these lesions, it would
bepredicted tooccur inSchwanncell progenitors, as this lineage
drives tumor development. Therefore, nuclear markers of
Schwann cell progenitors were examined: specifically AP2-a
and Krox-20. AP2-a is a transcription factor that is expressed
in neural crest stem cells, and its expression is terminated as
Schwann cell precursors differentiate into embryonic Schwann
cells (Stewart et al., 2001). Krox-20 is expressed at a slightly later
stageofSchwanncell development (Ghislain et al., 2002), but im-
portantlymice carrying amutant floxedNf1 allele develop neuro-
fibromas when crossed to a Krox-20 Cre-expressing mouse
strain, indicating that Krox-20-expressing cells can serve as a
progenitor population capable of driving tumor development
(Zhu et al., 2002). Interestingly, the majority of SA-b-Gal-ex-
pressing cells expressed AP2-a and Krox-20. However, like
p16, not all AP2-a- or Krox-20-expressing cells expressed
SA-b-Gal (Figures 7E and 7F), indicating that not all of these cells
were undergoing senescence at the time the tumor was re-
moved. Intriguingly, these results suggest that senescence oc-
curs in a Schwann cell progenitor population within human
neurofibromas.
Negative feedback signals occur in senescent
cells in human tumors
Our in vitro data indicated that the inactivation of the Ras path-
way participates in triggering senescence in response to NF1
deficiency. Activated ERK and AKT were readily detected in
the nuclei of a subset of cells scattered throughout the tumors;
however, p-ERK and p-AKT were never detected in the nuclei of
senescent cells, as determined by examining over 300 cells from
five individual tumors (Figures 7G and 7H). We also examined
FOXO1, a known target of AKT, that is exported to the cyto-
plasm upon phosphorylation, where it can be degraded (Greer
and Brunet, 2005). Notably, FOXO1 was exclusively detected
in the nuclei of senescent cells, further supporting the conclu-
sion that AKT is inactivated in these cells and that this signal re-
sults in the activation of FOXO proteins (Figure 7H). Collectively,
these results indicate that the negative feedback response that
wedissected in vitro also occurs in vivo, specifically within a sen-
escent population of cells within benign tumors. These data sug-
gest that this negative feedback loop coordinately functions468with previously identified signals to mediate oncogene-induced
senescence.
Discussion
The cellular mechanisms that suppress tumorigenesis have
been investigated for many years. However, while apoptosis is
a widely accepted mechanism of tumor suppression, onco-
gene-induced senescence has been more controversial. Never-
theless, a series of recent papers have demonstrated that Ras,
Raf, and PTEN mutations trigger senescence in vivo in human
and mouse tumors (Braig et al., 2005; Chen et al., 2005; Collado
et al., 2005; Michaloglou et al., 2005). Moreover, these studies
demonstrated that senescence exclusively occurs in benign tu-
mors, indicating that itmay function toprevent theprogression of
these lesions. However, the precise mechanisms that mediate
oncogene-induced senescence have not been fully elucidated.
A revised model of oncogene-induced senescence
In this study, we show that the aberrant activation of endoge-
nous Ras can induce dramatically different phenotypes in differ-
ent cell types. In MEFs, loss of the NF1 tumor suppressor results
in sustained Ras activation, a hypersensitivity to growth factors,
and immortalization. However, in normal human diploid fibro-
blasts loss of NF1 triggers a transient activation of Ras and
Ras effectors, followed by a dramatic suppression of these sig-
nals to lower than baseline levels. Moreover, these cells are not
immortalized, but rather become senescent. Our results indicate
that, in ‘‘sensitive’’ cell types, the ultimate response to the aber-
rant activation of the Ras pathway is a dramatic termination of
Ras signaling at many levels, followed by a cellular response
designed to eliminate the proliferative potential of these cells.
Furthermore, this sensitivity is not determined by a single bio-
chemical event, but rather by the coordinated output of cell
type-specific signaling networks.
The central conclusion from this study is that the consequen-
tial suppression of Ras and/or PI3K is an unappreciated signal
that contributes to oncogene-induced senescence (Figure 8).
Several observations support this conclusion. First, Ras effector
pathways are rapidly extinguished in response to NF1 loss, and
Raf and Rasmutations, prior to the onset of senescence. In ad-
dition, suppression of Ras and/or PI3K is sufficient to induce se-
nescence, and these events on their own can activate the known
downstream mediators of the senescence response (Rb and
p53) through a variety of mechanisms. Prior to this study, onco-
gene-induced senescence was thought to be primarily medi-
ated by p16 and ARF. However, recent studies support the
involvement of additional uncharacterized signals in the senes-
cence response. For example, in primary melanocytes an acti-
vated Raf allele induced p16 expression but did not induce
ARF (Michaloglou et al., 2005). Nevertheless, the ablation of
p16 had no effect on senescence induced by this oncogenic
Raf allele. A similar anomaly was observed in vivo, as melano-
cytic nevi from p16-deficient Leiden patients, albeit larger, still
underwent a growth arrest (Gruis et al., 1995). Therefore, it has
been suggested that there are additional signals that collaborate
with p16 to promote or establish senescence (Michaloglou et al.,
2005). Our data suggest that the negative feedback suppression
of the Ras/PI3K pathway, and its downstream consequences
(inhibition of HDM2 and activation of FOXO proteins, among
others), represent such signals. Thus, we propose a modelCANCER CELL DECEMBER 2006
A R T I C L EFigure 8. Revised model of oncogene-induced senescence
A: In cells that are insensitive to oncogene-induced senescence, activation of the Ras pathway leads to hyperactivation of well-known effector pathways,
which function to promote tumorigenesis.
B: In sensitive cells the ultimate response to the aberrant activation of the Ras pathway is the initiation of a multifaceted negative feedback signaling network
designed to terminate the oncogenic signal. These signals are triggered by the Raf/MEK/ERK pathway and involve numerous transcriptional and posttrans-
lational events, including the suppression of Ras exchange factors, and the upregulation of Sprouty proteins and RasGAPs, among others. These inhibitory
signals, via the consequential suppression of PI3K, can activate Rb and p53 through multiple signals. Thus, we propose that oncogene-induced senescence
is mediated by this negative feedback signaling program, which functions along with other known senescence regulators, such as p16 and ARF, to achieve
a threshold senescence signal.whereby an oncogenic insult can trigger multiple inhibitory sig-
nals that may vary, depending on the genetic event and the spe-
cific signaling network components that are present in a particu-
lar cell type. In cells with intact p53 and Rb pathways, we
propose that these signals cooperate to achieve a threshold
response, thereby inducing cellular senescence.
The existence of multiple negative feedback pathways de-
signed to inhibit Ras signaling makes teleological sense, in that
it would be advantageous to immediately terminate the effects
of aberrant Ras signaling at many levels. Notably however, in re-
sponse to Raf mutations and NF1 loss, many of these negative
feedback signals are directed toward Ras itself. Minimally, this
regulation is likely to involve three families of proteins: RasGAPs,
RasGEFs, and Sprouty proteins. It is particularly notable that
Sprouty genes were highly expressed in both Raf-expressing
and NF1-deficient cells. Interestingly, a recent microarray study
identified a Sprouty gene as one of the genes differentially upre-
gulated in benign human neurofibromas as compared to malig-
nant tumors (Holtkamp et al., 2004), further supporting the hy-
pothesis that this class of genes may be involved in limiting the
development of these benign lesions. In any case, it is tempting
to speculate that these negative regulatory proteins may be un-
appreciated tumor suppressors and may ultimately be shown to
be mutational targets in cancer.
PI3K and its role in senescence
Our data indicate that the suppression of PI3K, in particular, me-
diates the senescence response. These findings explain theCANCER CELL DECEMBER 2006longstanding observation that MEFs lacking the PI3K p85a
and -b subunits cannot be generated, as they undergo prema-
ture senescence (Brachmann et al., 2005). In addition, the ob-
servation that aberrant Raf activation potently suppresses
PI3K signaling provides one mechanistic explanation for the
known cooperativity of Raf and PTEN mutations in human tu-
mors (Tsao et al., 2004). Interestingly, we found that Raf not
only suppressed PI3K signaling, but as a consequence stimu-
lated FOXO activity, revealing an additional unexpected con-
nection between these two pathways. Notably, FOXO genes
have been hypothesized to function as tumor suppressors
(Greer and Brunet, 2005). Moreover, we found that the expres-
sion of a constitutively activated FOXO protein rapidly triggered
senescence. Taken together, these data raise the intriguing pos-
sibility that FOXO proteins may specifically function in tumors
harboring activated Raf alleles. Nevertheless, the consequential
suppression of PI3K in response to Raf or NF1 mutations may
mediate its effects via a number of mechanisms, involving
FOXO, HDM2, or other signals. Regardless, the observation
that multiple negative feedback pathways are activated in this
context underscores the potential importance of these events
in tumor suppression.
On the surface, this model appears to contradict recent find-
ings indicating that the activation of PI3K, through loss of PTEN,
also triggers senescence (Chen et al., 2005). We also found that
loss of PTEN induced senescence in human cells, but we found
no evidence of Ras suppression or a decrease in pAKT levels
(unpublished data). However, these data do not exclude the469
A R T I C L Epossibility that a negative feedback event may occur some-
where downstream of AKT. Regardless, these findings indicate
that PI3K may be a critical sensor and regulator of the senes-
cence response. Too little or too much PI3K activity can trigger
senescence, the former mediated by the mechanisms de-
scribed above, the latter perhaps resulting from the induction
of ARF and p53, as has been previously suggested (Chen
et al., 2005). Nevertheless, in the context of Raf mutations and
NF1 deficiency (in vitro and in vivo), negative feedback signals
designed to suppress PI3K signaling appear to predominate;
the PI3K/AKT pathway is rapidly suppressed in both instances,
and consequential downstream signals are engaged.
Negative feedback signals mediate senescence in vivo
Finally, we show that these negative feedback pathways func-
tion in vivo in benign human tumors from NF1 patients. Strik-
ingly, in senescent cells within human neurofibromas, AKT and
ERK are completely suppressed and FOXO is activated. Ac-
cordingly, we hypothesize that these signals underlie the senes-
cence response in these lesions, thereby limiting the growth and
progression of these tumors. It has been suggested that senes-
cence might suppress tumor development, if it occurs in a stem
or progenitor cell population, resulting in the depletion of this
self-renewing pool of cells (Campisi, 2005). Previous studies
have not attempted to identify or characterize the senescent
population of cells in other benign tumors. In this regard it is no-
table that the majority of senescent cells in benign human neu-
rofibromas expressed both AP2-a and Krox-20, markers of early
Schwann cell progenitors. While the ‘‘cancer stem cell’’ in neu-
rofibromas remains to be identified, these observations indicate
that a relatively undifferentiated population of cells can become
senescent in these benign human tumors. If these cells repre-
sent the cancer stem cell or a critical progenitor population,
the senescence response may impede tumor development by
eliminating the proliferative capacity of this population of cells.
However, the challenge in the future will be to determine how
a subset of cells escape this self-limiting response.
Experimental procedures
Cell culture and infections
Human IMR90 and BJ fibroblasts were subcultured 1:2 except prior to infec-
tion, when they were split 1:3.Wild-type andNf12/2MEFswere generated as
described (Cichowski et al., 2003). Retroviral and lentiviral infections were
performed as described (Johannessen et al., 2005). The following constructs
were in the pBabe retroviral vector: H-RasV12, hNF1-GRD-HA, PTEN, p53DD,
and inducible estrogen receptor-Raf-1 (Raf1:ER). Large T and Large T D234-
444 were in pMKO.1. Sprouty 2 was in pMSCV. The pLKO.1 lentiviral vector
containing the following shRNAs were used: NF1#1, 50-CAACAACTTCAAT
GCAGTCTT-30; NF1#2, 50-TTATAAATAGCCTGGAAAAGG-30; p120RasGAP,
50-GCTGCCTAACTTATCCATCTT-30; PTEN, 50-CGTATACAGGAACAATAT
TG-30.
For experiments in which control cells were compared to shRNA-express-
ing cells, cells were split to an equal cell density 16 hr prior to harvesting. The
following inhibitors were used: 50 mM PD98059 (Calbiochem), 30–50 mM
LY294002 (Calbiochem), and 100 nMwortmannin (Sigma-Aldrich).Wortman-
nin was re-added to themedia every 3 hr during the first 12 hr, the media was
changed every 24 hr (and this protocol was repeated daily). Other inhibitors
were added daily with fresh media.
Growth curves
IMR90 fibroblasts were infected and selected for 2 days with puromycin
(2 mg/ml). Cells (2.0 3 105) were seeded in triplicate in 10 cm plates. Cells
were counted and seeded at a density of 2.0 3 105 every 4 days, for five470passages. Population doublings (PD) were determined by the following for-
mula: PD = Log (Nf/Ni)/Log2, where Nf = the number of cells counted and
Ni = the number of cells seeded (2.0 3 105). Cumulative PD numbers repre-
sent the sum of PDs from all previous passages. For MEFs, 3.0 3 105 cells
were seeded in 6 cmdishes, counted every 3 days, and reseeded at a density
of 3.0 3 105 (Sage et al., 2000).
SA-b-Gal activity
SA-b-Gal staining was performed as described (Dimri et al., 1995), and per-
centages were assessed by counting at least 300 cells. For human neurofi-
bromas, tumor tissue was obtained immediately after surgery, and small
pieces were fixed for 30 min in 3% paraformaldehyde, incubated as de-
scribed above, and then embedded and sectioned.
Immunoblotting
Western analysis and immunoprecipitations were performed as described
(Johannessen et al., 2005) using the following antibodies: phospho-Akt, total
Akt, phospho-Erk, total ERK, ph-HDM2 (Cell Signaling Technology); protein
kinase Ba/AKT1, actin, b-Tubulin, RASA3 (Sigma-Aldrich); p120RasGAP
(Transduction Laboratories); neurofibromin (UP69: a polyclonal antibody de-
signed to recognize the C terminus of neurofibromin), p53 (PAb 240 clone),
Sprouty 2, Sprouty 4, MKP3, RasGRP1, p16 (Santa Cruz Biotechnologies);
pRB, p16INK4a (BD Pharmingen); SOS1 (Upstate); p53 (DO7) (Signet).
Histology
Histological sectionswere cut into 5mmsections fromparaffin-embedded tis-
sue and stained with H&E where indicated. Unmasking was performed with
sodium citrate buffer (pH 6.0). Antibody dilutions and preferred buffers are
as follows: 1:100 NF1 antibody (4C O/N, sc-67, Santa Cruz), 1:50 (TBST)
p16INK4a (Ab-7, MS-1064-P, Neomarkers), 1:100 (PBS) AP-2 a (clone 3B5,
Developmental Studies Hybridoma Bank, University of Iowa), 1:50 (TBST)
Krox-20 (PRB-236P, Covance), 1:50 (TBST) phospho-p44/42 MAPK
(#4376, Cell Signaling Technology), 1:50 (TBST) phospho-AKT (#3787, Cell
SignalingTechnology), 1:50 (PBS) FOXO1 (#9462,Cell Signaling Technology).
Antibodies were detected using the Vectastain Elite Universal Kit (PK-6200,
Vector Laboratories).
Ras activation analysis
Ras-GTP levels were detected using a Ras activation assay, following the
manufacturer’s instructions (Upstate Biotechnology).
Luciferase assay
BJ fibroblasts, stably expressing the inducible Raf construct, were seeded
in triplicate in 24-well plates, at a density of 105 cells per well and treated
with ethanol or 1 mM of tamoxifen (Calbiochem). Cells were transfected
with 0.25 mg of the FKHR (FOXO1) or FKHRL1 (FOXO3) plasmid, 0.5 mg of
the Luciferase reporter gene, 0.25 mg of the pRL, and 1 mg of carrier DNA.
Forty-eight hours later, cells were lysed, and one-fifth of the sample was
assayed according to the Promega luciferase protocol.
Real-time PCR
Real-time PCR reactions were performed in triplicate using the Assays-on-
Demand Taqman Gene Expression Assays from Applied Biosystems. Probe
sets and methods are described in Figure S5.
Statistical analysis
All numerical data including error bars represent the mean 6 the standard
deviation.
Human subjects
The Office of Research Protections ruled that this study does not represent
human subjects research due to exemption 32 CFR 219.101(b)4: the re-
search involved collection or study of existing pathological specimens that
are publicly provided without identifiers.
Supplemental data
The Supplemental Data include five supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/10/6/
459/DC1/.CANCER CELL DECEMBER 2006
A R T I C L EAcknowledgments
We thank Lew Cantley, Ben Neel, Anne Brunet, Reuben Shaw, Sheila
Thomas, and Jeff Engelman for helpful discussions. We thank the Broad In-
stitute RNAi consortium (TRC) and William Hahn for providing shRNA con-
structs and William Hahn for the LgT constructs. We thank Martin McMahon
for the Raf:ER construct, Jeff Engelman for the PTEN shRNA construct, and
Nir Hacohen for the Sprouty 2 construct. The microarray analysis was per-
formed by the Biopolymers Facility at Harvard Medical School. This work
was supported by grants from the DOD (DAMD17-03-1-0350) and the NCI
(R01 CA111754-01).
Received: June 9, 2006
Revised: August 9, 2006
Accepted: October 3, 2006
Published: December 11, 2006
References
Basu, T.N., Gutmann, D.H., Fletcher, J.A., Glover, T.W., Collins, F.S., and
Downward, J. (1992). Aberrant regulation of ras proteins in malignant tumour
cells from type 1 neurofibromatosis patients. Nature 356, 713–715.
Bollag, G., Clapp, D.W., Shih, S., Adler, F., Zhang, Y.Y., Thompson, P.,
Lange, B.J., Freedman, M.H., McCormick, F., Jacks, T., and Shannon, K.
(1996). Loss of NF1 results in activation of the Ras signaling pathway and
leads to aberrant growth in haematopoietic cells. Nat. Genet. 12, 144–148.
Brachmann, S.M., Yballe, C.M., Innocenti, M., Deane, J.A., Fruman, D.A.,
Thomas, S.M., and Cantley, L.C. (2005). Role of phosphoinositide 3-kinase
regulatory isoforms in development and actin rearrangement. Mol. Cell.
Biol. 25, 2593–2606.
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A.H., Schlegel-
berger, B., Stein, H., Dorken, B., Jenuwein, T., and Schmitt, C.A. (2005). On-
cogene-induced senescence as an initial barrier in lymphoma development.
Nature 436, 660–665.
Campisi, J. (2005). Senescent cells, tumor suppression, and organismal
aging: Good citizens, bad neighbors. Cell 120, 513–522.
Chen, Z., Trotman, L.C., Shaffer, D., Lin, H.K., Dotan, Z.A., Niki, M., Koutcher,
J.A., Scher, H.I., Ludwig, T., Gerald, W., et al. (2005). Crucial role of p53-de-
pendent cellular senescence in suppression of Pten-deficient tumorigenesis.
Nature 436, 725–730.
Cichowski, K., and Jacks, T. (2001). NF1 tumor suppressor gene function:
Narrowing the GAP. Cell 104, 593–604.
Cichowski, K., Santiago, S., Jardim, M., Johnson, B.W., and Jacks, T. (2003).
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor sup-
pressor. Genes Dev. 17, 449–454.
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A.J., Barradas, M.,
Benguria, A., Zaballos, A., Flores, J.M., Barbacid, M., et al. (2005). Tumour
biology: Senescence in premalignant tumours. Nature 436, 642.
Corbalan-Garcia, S., Yang, S.S., Degenhardt, K.R., and Bar-Sagi, D. (1996).
Identification of the mitogen-activated protein kinase phosphorylation sites
on human Sos1 that regulate interaction with Grb2. Mol. Cell. Biol. 16,
5674–5682.
DeClue, J.E., Papageorge, A.G., Fletcher, J.A., Diehl, S.R., Ratner, N., Vass,
W.C., and Lowy, D.R. (1992). Abnormal regulation ofmammalian p21ras con-
tributes to malignant tumor growth in von Recklinghausen (type 1) neurofi-
bromatosis. Cell 69, 265–273.
Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano,
E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al. (1995). A biomarker that
identifies senescent human cells in culture and in aging skin in vivo. Proc.
Natl. Acad. Sci. USA 92, 9363–9367.
Dong, C., Waters, S.B., Holt, K.H., and Pessin, J.E. (1996). SOS phosphory-
lation and disassociation of the Grb2-SOS complex by the ERK and JNK sig-
naling pathways. J. Biol. Chem. 271, 6328–6332.CANCER CELL DECEMBER 2006Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy.
Nat. Rev. Cancer 3, 11–22.
Ghislain, J., Desmarquet-Trin-Dinh, C., Jaegle, M., Meijer, D., Charnay, P.,
and Frain, M. (2002). Characterisation of cis-acting sequences reveals a bi-
phasic, axon-dependent regulation of Krox20 during Schwann cell develop-
ment. Development 129, 155–166.
Greer, E.L., and Brunet, A. (2005). FOXO transcription factors at the interface
between longevity and tumor suppression. Oncogene 24, 7410–7425.
Gruis, N.A., van der Velden, P.A., Sandkuijl, L.A., Prins, D.E., Weaver-Feld-
haus, J., Kamb, A., Bergman, W., and Frants, R.R. (1995). Homozygotes
for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.
Nat. Genet. 10, 351–353.
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M.,
Campuzano, V., and Barbacid, M. (2003). Tumor induction by an endoge-
nous K-ras oncogene is highly dependent on cellular context. Cancer Cell
4, 111–120.
Hahn, W.C., Dessain, S.K., Brooks, M.W., King, J.E., Elenbaas, B., Sabatini,
D.M., DeCaprio, J.A., and Weinberg, R.A. (2002). Enumeration of the simian
virus 40 early region elements necessary for human cell transformation. Mol.
Cell. Biol. 22, 2111–2123.
Hiatt, K.K., Ingram, D.D., Zhang, Y., Bollag, G., and Clapp, D.W. (2001). Neu-
rofibromin GTPase-activating protein-related domains restore normal
growth in Nf12/2 cells. J. Biol. Chem. 276, 7240–7245. Published online
November 15, 2000. 10.1074/jbc.M009202200.
Holtkamp, N., Mautner, V.F., Friedrich, R.E., Harder, A., Hartmann, C., The-
allier-Janko, A., Hoffmann, K.T., and vonDeimling, A. (2004). Differentially ex-
pressed genes in neurofibromatosis 1-associated neurofibromas and malig-
nant peripheral nerve sheath tumors. Acta Neuropathol. (Berl.) 107, 159–168.
Johannessen, C.M., Reczek, E.E., James, M.F., Brems, H., Legius, E., and
Cichowski, K. (2005). The NF1 tumor suppressor critically regulates TSC2
and mTOR. Proc. Natl. Acad. Sci. USA 102, 8573–8578.
Kim, H.J., and Bar-Sagi, D. (2004). Modulation of signalling by Sprouty: A de-
veloping story. Nat. Rev. Mol. Cell Biol. 5, 441–450.
Kim, H.A., Rosenbaum, T., Marchionni, M.A., Ratner, N., and DeClue, J.E.
(1995). Schwann cells from neurofibromin deficient mice exhibit activation
of p21ras, inhibition of cell proliferation and morphological changes. Onco-
gene 11, 325–335.
Michaloglou, C., Vredeveld, L.C., Soengas, M.S., Denoyelle, C., Kuilman, T.,
van der Horst, C.M., Majoor, D.M., Shay, J.W., Mooi, W.J., and Peeper, D.S.
(2005). BRAFE600-associated senescence-like cell cycle arrest of human
naevi. Nature 436, 720–724.
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K.,
Masuyama, N., and Gotoh, Y. (2002). Akt enhances Mdm2-mediated ubiqui-
tination and degradation of p53. J. Biol. Chem. 277, 21843–21850.
Ohtani, N., Zebedee, Z., Huot, T.J., Stinson, J.A., Sugimoto, M., Ohashi, Y.,
Sharrocks, A.D., Peters, G., and Hara, E. (2001). Opposing effects of Ets and
Id proteins on p16INK4a expression during cellular senescence. Nature 409,
1067–1070.
Riccardi, V.M. (1992). Neurofibromatosis: Phenotype, Natural History, and
Pathogenesis, Second Edition (Baltimore: The Johns Hopkins University
Press).
Sage, J., Mulligan, G.J., Attardi, L.D., Miller, A., Chen, S., Williams, B., Theo-
dorou, E., and Jacks, T. (2000). Targeted disruption of the three Rb-related
genes leads to loss of G(1) control and immortalization. Genes Dev. 14,
3037–3050.
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997).
Oncogenic ras provokes premature cell senescence associated with accu-
mulation of p53 and p16INK4a. Cell 88, 593–602.
Seshadri, T., and Campisi, J. (1990). Repression of c-fos transcription and an
altered genetic program in senescent human fibroblasts. Science 247, 205–
209.
Stewart, H.J., Brennan, A., Rahman, M., Zoidl, G., Mitchell, P.J., Jessen,
K.R., and Mirsky, R. (2001). Developmental regulation and overexpression471
A R T I C L Eof the transcription factor AP-2, a potential regulator of the timing of Schwann
cell generation. Eur. J. Neurosci. 14, 363–372.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J.J.,
Ladd-Acosta, C., Mesirov, J., Golub, T.R., and Jacks, T. (2005). An onco-
genic KRAS2 expression signature identified by cross-species gene-expres-
sion analysis. Nat. Genet. 37, 48–55.
Tresini, M., Mawal-Dewan, M., Cristofalo, V.J., and Sell, C. (1998). A phos-
phatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in
human diploid fibroblasts. Cancer Res. 58, 1–4.
Tsao, H., Goel, V., Wu, H., Yang, G., and Haluska, F.G. (2004). Genetic inter-
action between NRAS and BRAF mutations and PTEN/MMAC1 inactivation
in melanoma. J. Invest. Dermatol. 122, 337–341.
Tuveson, D.A., Shaw, A.T., Willis, N.A., Silver, D.P., Jackson, E.L., Chang, S.,
Mercer, K.L., Grochow, R., Hock, H., Crowley, D., et al. (2004). Endogenous472oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic
and developmental defects. Cancer Cell 5, 375–387.
Wei, S., and Sedivy, J.M. (1999). Expression of catalytically active telomerase
does not prevent premature senescence caused by overexpression of onco-
genic Ha-Ras in normal human fibroblasts. Cancer Res. 59, 1539–1543.
Wei, W., Hemmer, R.M., and Sedivy, J.M. (2001). Role of p14(ARF) in replica-
tive and induced senescence of human fibroblasts. Mol. Cell. Biol. 21, 6748–
6757.
Zhu, J., Woods, D., McMahon, M., and Bishop, J.M. (1998). Senescence of
human fibroblasts induced by oncogenic Raf. Genes Dev. 12, 2997–3007.
Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K., and Parada, L.P. (2002). Neuro-
fibromas in NF1: Schwann cell origin and role of tumor environment. Science
296, 920–922.CANCER CELL DECEMBER 2006
